205 related articles for article (PubMed ID: 9916332)
41. [Research on foreign countries laws and regulations on surveillance and reporting of postmarketing drugs adverse reactions].
Tian F; Xie Y
Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1464-7. PubMed ID: 19771884
[TBL] [Abstract][Full Text] [Related]
42. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Hauben M; Reich L; Gerrits CM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
[TBL] [Abstract][Full Text] [Related]
43. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
44. Adverse drug reactions: a review of relevant factors.
Ajayi FO; Sun H; Perry J
J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
[TBL] [Abstract][Full Text] [Related]
45. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
46. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
[TBL] [Abstract][Full Text] [Related]
47. Highlights of the 22nd French pharmacovigilance meeting.
Prescrire Int; 2002 Feb; 11(57):21-3. PubMed ID: 11985373
[TBL] [Abstract][Full Text] [Related]
48. [Update of the French drug reaction assessment method].
; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
Therapie; 2011; 66(6):517-25. PubMed ID: 22186077
[TBL] [Abstract][Full Text] [Related]
49. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center.
Lindquist M; Edwards IR
J Rheumatol; 2001 May; 28(5):1180-7. PubMed ID: 11361210
[TBL] [Abstract][Full Text] [Related]
50. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
Ball D
Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
[No Abstract] [Full Text] [Related]
51. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
Harrison-Woolrych M; Hill GR; Clark DW
Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
[TBL] [Abstract][Full Text] [Related]
52. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project--six sites, United States, January 1-June 15, 2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Apr; 54(15):380-3. PubMed ID: 15843786
[TBL] [Abstract][Full Text] [Related]
53. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants].
Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML
Therapie; 1997; 52(2):97-103. PubMed ID: 9231502
[TBL] [Abstract][Full Text] [Related]
54. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES).
Jhung MA; Budnitz DS; Mendelsohn AB; Weidenbach KN; Nelson TD; Pollock DA
Med Care; 2007 Oct; 45(10 Supl 2):S96-102. PubMed ID: 17909391
[TBL] [Abstract][Full Text] [Related]
55. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
56. Postmarketing surveillance.
Oleen MA
Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
[TBL] [Abstract][Full Text] [Related]
57. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
Avouac B
Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
[TBL] [Abstract][Full Text] [Related]
59. Advantages of adverse-effect reporting by patients.
Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
[No Abstract] [Full Text] [Related]
60. Methods for improving the reporting of adverse effects.
Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
